Active Clinical Research Studies

Excell Research may be seeking participants for an upcoming clinical research study for an area or disease that is relevant to you or someone you know.

Clinical Research Trials

Clinical research trials and those who contribute play a role in the development of new treatments for some of our most common and debilitating diseases and conditions.

Patients who participate in Excell’s clinical research trials have an opportunity to join the vanguard of scientific research and contribute to the progress, knowledge, and future treatment of medical conditions.

We will provide you with comprehensive information and straightforward answers to your questions regarding the risks and benefits of participating.

Financial compensation may be available to those who qualify and complete visits for clinical trials at Excell.

Sign up for a trial today!

Depression Clinical Research Studies

Sponsor:

Alto Neuroscience

Protocol Number:

ALTO-100-201

Summary: The ALTO-100-201 study is evaluating the safety and efficacy of ALTO-100 used either as monotherapy or adjunctively to an antidepressant. The study includes an optional 4-week open-label portion and is 8 or 16 weeks with 12 potential study visits.

Eligibility Criteria

Key Inclusion Criteria:

  • Symptoms of depression for at least 6 weeks prior to entering the study.
  • Willing to comply with all study assessments and procedures.
  • Willing to either not take an antidepressant medication, or continue taking a single SSRI, SNRI, mirtazapine, or bupropion with no dose changes 2 weeks prior to medication or placebo distribution.

Key Exclusion Criteria:

  • Diagnosed with bi-polar disorder, schizophrenia, psychotic disorders, or dementia.
  • Primary symptoms of post-traumatic stress disorder.
  • Clinically significant medical conditions.
  • History of substance abuse in the past 3 months.

Patient Time Reimbursed?

Yes

Patient Travel Reimbursed?

Yes

Age:

18-70

Clinicaltrials.gov Linkhttps://clinicaltrials.gov/study/NCT05712187?term=ALTO-100-201&cond=Depression&rank=1&tab=table

Generalized Anxiety Clinical Research Studies

Sponsor:

Sunovion Pharmaceuticals

Protocol Number:

SEP361-226

Summary: The Periscope study is a placebo-controlled study evaluating the safety and efficacy of SEP361 n adults with Generalized Anixety Disorder.

 

Eligibility Criteria:

Key Inclusion Criteria:

  • Male or female subject between 18 to 65 years of age.
  • Symptoms of Generalized Anxiety Disorder over the past 6 months.
  • Primary focus of treatment is Generalized Anxiety Disorder.

Key Exclusion Criteria:

  • Diagnosis other than Generalized Anxiety Disorder that was the primary focus of treatment within 12 months before Screening.
  • Previous inadequate response to more than 3 antidepressant treatments.
  • Any clinically significant unstable medical condition or any clinically significant chronic disease, that would limit the subject’s ability to complete and/or participate in the study.

Patient Time Reimbursed?

Yes

Patient Travel Reimbursed?

Yes

Age:

18 to 65

Clinicaltrials.gov Link:

https://clinicaltrials.gov/study/NCT05729373?term=SEP361-226&aggFilters=status:rec&rank=1&tab=table

Sponsor Website:

Sunovion Pharmaceuticals Inc. – New England Journal of Medicine Publishes Pivotal Results Evaluating Sunovion’s SEP-363856 for the Treatment of Schizophrenia

Schizophrenia Clinical Research Studies

Sponsor:

Neurocrine

Study Name:

Erudite Study

Protocol Number:

NBI-1065844-CIAS2023

Summary: The Erudite study is evaluating the safety, efficacy, and tolerability of Luvadaxistat in subjects with cognitive impairment associated with schizophrenia.

Eligibility Criteria

Key Inclusion Criteria:

  • Experiencing cognitive impairment with a previous diagnosis of Schizophrenia.
  • Willing to comply with all study assessments and procedures.
  • Currently taking an antipsychotic medication for at least 3 weeks prior to study entry at a 2-6mg Risperidone equivalent.

Key Exclusion Criteria:

  • Diagnosed with bi-polar disorder or other non-schizophrenic psychotic disorders.
  • Current substance/alcohol abuse.
  • Clinically significant medical conditions.

Patient Time Reimbursed?

Yes

Patient Travel Reimbursed?

Yes

Age:

18-50

Clinicaltrials.gov Linkhttps://clinicaltrials.gov/ct2/show/NCT05182476?term=NBI-1065844-CIAS2023&draw=2&rank=1

Sponsor Websitehttps://www.neurocrine.com/

OCD Clinical Research Studies

Sponsor:

Biohaven Pharmaceuticals

Study Name:

Biohaven Study

Protocol Number:

BHV4157-302

Summary: The Biohaven study is a placebo-controlled study evaluating the safety and efficacy of Troriluzole n adults taking an SSRI to treat symptoms of obsessive-compulsive disorder.

Eligibility Criteria:

Key Inclusion Criteria:

  • Experiencing moderate to severe symptoms of obsessive-compulsive disorder in the past year.
  • Currently taking an SSRI medication for 8 weeks prior to study entry. (Zoloft, Prozac, Lexapro, Celexa, ect.)
  • Willing to stop exclusionary psychiatric medications prior to study entry.

Key Exclusion Criteria:

  • Lifetime history of bi-polar disorder, schizophrenia, borderline personality disorder or autism spectrum disorders.
  • Unwilling to discontinue exclusionary medications or comply with study procedures.
  • Any clinically significant unstable medical condition or any clinically significant chronic disease.

Patient Time Reimbursed?

Yes

Patient Travel Reimbursed?

Yes

Age:

18 to 65

Clinicaltrials.gov Link:

https://clinicaltrials.gov/ct2/show/NCT04641143?term=BHV4157-302&draw=2&rank=1

Sponsor Website:

https://www.biohaven.com/

Adolescent Migraine Clinical Research Studies

Sponsor:

AbbVie

Name:

Periscope Study

Protocol Number:

3110-305-002

Summary: The Periscope study is a placebo-controlled study evaluating the safety and efficacy of Ubrogepant in acute treatment of migraine with or without aura in children and adolescents.

Eligibility Criteria

Key Inclusion Criteria:

  • History of 1 to 14 migraine attacks per month with moderate to severe headaches in each of the 2 months prior to study entry.
  • Current or past use of at least 1 oral medication (over-the-counter medication or prescription medication) for the acute treatment of migraine.

Key Exclusion Criteria:

  • Any clinically significant hematologic, endocrine, pulmonary, renal, hepatic, gastrointestinal, cardiovascular, or neurologic disease.
  • Other confounding pain syndromes, confounding psychiatric conditions, or other significant neurological disorders other than migraine.

Patient Time Reimbursed?

Yes

Patient Travel Reimbursed?

Yes

Age:

12-17

Clinicaltrials.gov Linkhttps://clinicaltrials.gov/ct2/show/study/NCT05125302?term=3110-305-002&draw=2&rank=2

Sponsor Websitehttps://www.abbvie.com/who-we-are.htmlhttps://www.abbvie.com/who-we-are.html?utm_medium=psearch&utm_campaign=corprepppp_2023&utm_source=google&utm_content=igp&utm_term=brandcore&cid=ppc_CV5d23f5fe9b1d494480b4c5bdc9a98b4d&gclid=CjwKCAjw-b-kBhB-EiwA4fvKrPKcFLoo52XYUNnDKWdQW20OpCRUZU5roVmk_UOLWa

Alzheimer's Disease Clinical Research Studies

Sponsor:

Otsuka Pharmaceutical Development:

Name:

Aspect Study

Protocol Number:

20-AVP-786-306

Summary: The Aspect study is a placebo-controlled study evaluating the safety and efficacy of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer’s Type.

Eligibility Criteria

Key Inclusion Criteria:

  • Probable diagnosis of Dementia of the Alzheimer’s type.
  • Caregiver participation required.

Key Exclusion Criteria:

  • Dementia other than Alzheimer’s Disease.
  • Not currently in any assisted living facility.
  • No history of seizures, severe eating disorder or any condition that increases risk of seizures.
  • No hospitalization in a mental health facility or living alone.

Patient Time Reimbursed?

Yes

Patient Travel Reimbursed?

Yes

Age:

50-90

Clinicaltrials.gov Linkhttps://clinicaltrials.gov/ct2/show/NCT04408755?term=20-AVP-786-306&draw=2&rank=1

Sponsor Websitehttps://www.otsuka-us.com/

Excell Research Clinical Research StudiesWhy Participate?

For those interested in participating in clinical research trials, Excell has a variety of studies that are testing new or investigational medications at no cost to clinical research study participants! Learn more about how new treatments may help with your symptoms.

https://excellresearch.com/wp-content/uploads/2023/08/qtq80-VpnKce.jpeg

Participants

Clinical research trials create a new opportunity for patients to receive alternative or more varied treatment, and to get up close and personal treatment from healthcare professionals. Often, Clinical research trials provide financially viable treatment options that may not have otherwise been available. By participating in a clinical research study, you would be aiding healthcare officials in their efforts to advance medical knowledge and to find new and better treatment options for patients.

 

New Treatments For Longer and Better-Quality Lives

The primary goal of all clinical research trial is to determine that the new treatment is both effective and safe for patients. A clinical trial may seek a cure or new methods to ease the lives of patients with chronic illnesses. Participating in a clinical research trial allows you to receive the most cutting-edge treatment or procedures in the medical field, and to assist in helping other patients live longer and better-quality lives.

 

Patient Safety

To ensure the safety of patients during clinical research trials, Excell follows guidelines set by organizations such as the U.S. Food & Drug Administration and the Global International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use Good Clinical Practices (ICH GCP).

According to requirements of the Medical Board of California, medical providers at Excell Research are providing information about the Open Payments Database.  The Open Payments database is a federal tool used to search payments made by drug and device companies to physicians and teaching hospitals. It can be found at https://openpaymentsdata.cms.gov.  This database was created so that patients can be informed of any possible influence pharmaceutical companies may have on their physician.  As a dedicated research facility, the entirety of Excell Research’s income is from pharmaceutical companies; however, medical providers are paid for their work by Excell Research and not directly by any pharmaceutical company.

Learn more about the company on the About Us page.

Clinical Trials at ExcellSign up for monthly updates for Clinical trials at Excell.

In partnership with Researchify Health, refer someone you known or sign up to receive digital communications about current and upcoming studies at Excell.
https://excellresearch.com/wp-content/uploads/2023/08/qtq80-lHlUrD.jpeg